Movano Health Provides Update on FDA Review of EvieMED Ring
Rhea-AI Summary
Movano Health (Nasdaq: MOVE) provided an update on the FDA review of its EvieMED Ring. The company received additional clarifying questions from the FDA related to medical aspects of the device, as part of the final phase of its 510(k) application review process. Movano Health remains optimistic about EvieMED's potential for 510(k) clearance after securing a positive resolution to initial FDA questions about wellness features and metrics.
The EvieMED Ring is designed to provide medical device functionality through pulse oximetry, along with wellness metrics for sleep, activity, and mood tracking. Separately, Movano Health successfully resumed direct-to-consumer orders for the Evie Ring on September 17, 2024, with initial positive response to product and operational improvements.
Positive
- Positive resolution to initial FDA questions about EvieMED Ring's wellness features
- Optimism about potential 510(k) clearance for EvieMED Ring
- Successful resumption of direct-to-consumer orders for Evie Ring
- Positive initial response to product and operational improvements
Negative
- Additional FDA questions about medical aspects of EvieMED Ring, potentially delaying approval
News Market Reaction – MOVE
On the day this news was published, MOVE declined 1.23%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The Company continues to work closely with the FDA to bring this pioneering healthcare product to market
"The FDA 510(k) clearance process is a rigorous one and we are pleased with the progress we continue to make," said John Mastrototaro, President and CEO of Movano Health. "We are confident we can effectively address the follow up questions that the Agency has submitted, and we look forward to completing the final review of the EvieMED Ring."
The EvieMED Ring is a wearable device designed to not only provide medical device functionality through its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity and logging of mood, energy and other characteristics.
Separately, Movano Health announced that it successfully commenced taking direct-to-consumer (D2C) orders again for the Evie Ring on September 17, 2024. With a fully organic marketing campaign, the Company is pleased with the initial response to product and operational improvements, including enhanced sleep, heart rate and activity monitoring, expanded AI-generated personalized insights, and upgrades across manufacturing, logistics and customer service.
About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health, maker of the Evie Ring (www.eviering.com), is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. Featuring modern and flexible form factors, Movano Health's devices offer an innovative approach to delivering trusted data to both customers and enterprises, capturing a comprehensive picture of an individual's health data and uniquely translating it into personalized and intelligent insights.
Movano Health is developing its proprietary technologies and wearable medical device solutions to enable the future use of data as a tool to proactively monitor and manage health outcomes across a number of patient populations that exist in healthcare. For more information on Movano Health, visit https://movanohealth.com/.
Forward Looking Statements
This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding plans with respect to the commercial launches of the Evie Ring and EvieMED Ring; our expectations regarding potential commercial opportunities; planned cost-cutting initiatives; anticipated FDA clearance decisions with respect to our products; expected future operating results; product development and features, product releases, clinical trials and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/movano-health-provides-update-on-fda-review-of-eviemed-ring-302272214.html
SOURCE Movano
FAQ
What is the current status of Movano Health's EvieMED Ring FDA review?
When did Movano Health resume direct-to-consumer orders for the Evie Ring?
What features does the EvieMED Ring offer?
What improvements has Movano Health made to the Evie Ring?
